(BCUS) Exchange Listed Funds Trust - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • • Large Blend
BCUS: Common Stock, Preferred Stock, Convertible Securities
The Exchange Listed Funds Trust (NYSE ARCA: BCUS) is an actively managed exchange-traded fund (ETF) that focuses on equity securities, primarily investing in common stocks, preferred stocks, and securities convertible into common stock. The fund adheres to a large-cap equity strategy, concentrating on U.S.-listed companies with significant market capitalizations. Under normal market conditions, the ETF allocates at least 80% of its net assets (plus borrowings for investment purposes) to these securities, ensuring a strong emphasis on established, large-scale businesses. This approach aligns with the funds objective of capturing growth and income opportunities within the large-cap segment of the U.S. equity market.
As of the latest data, the fund has an average trading volume of 29,131 shares over the past 20 days, with a last price of $29.50. Its short-term and medium-term moving averages (SMA 20: $30.67, SMA 50: $30.73) suggest a recent dip below its average price levels, while the SMA 200 ($30.18) indicates a slightly lower long-term trend. The Average True Range (ATR) of 0.35 reflects relatively low volatility, suggesting stable price movements. With assets under management (AUM) of $100.99 million, the fund maintains a moderate size, balancing liquidity with focused exposure to large-cap equities.
3-Month Forecast: Based on the provided data, the funds price is expected to remain range-bound between $29.00 and $31.00 over the next three months. The SMA 20 and SMA 50 are currently above the last price, indicating potential short-term downward pressure. However, the SMA 200 provides a floor near $30.18, suggesting long-term support. The low ATR of 0.35 signals manageable volatility, with average daily price fluctuations of less than 1%. The funds AUM of $100.99 million indicates a stable investor base, which may contribute to consistent trading volumes and limited liquidity risks. Overall, the outlook is neutral, with a slight bias toward stabilization near the SMA 200 level.Additional Sources for BCUS ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BCUS ETF Overview
Market Cap in USD | 110m |
Category | Large Blend |
TER | 0.70% |
IPO / Inception | 2023-12-20 |
BCUS ETF Ratings
Growth 5y | 43.6% |
Fundamental | - |
Dividend | 1.0% |
Rel. Strength | -5.46 |
Analysts | - |
Fair Price Momentum | 26.54 USD |
Fair Price DCF | - |
BCUS Dividends
Dividend Yield 12m | 0.17% |
Yield on Cost 5y | 0.20% |
Annual Growth 5y | -100.00% |
Payout Consistency | 100.0% |
BCUS Growth Ratios
Growth Correlation 3m | -62.9% |
Growth Correlation 12m | 71.4% |
Growth Correlation 5y | 84.7% |
CAGR 5y | 13.15% |
CAGR/Max DD 5y | 1.08 |
Sharpe Ratio 12m | -0.19 |
Alpha | -2.52 |
Beta | 0.000 |
Volatility | 14.67% |
Current Volume | 2.8k |
Average Volume 20d | 4.7k |
As of March 31, 2025, the stock is trading at USD 29.15 with a total of 2,800 shares traded.
Over the past week, the price has changed by -1.86%, over one month by -3.11%, over three months by -4.24% and over the past year by +1.88%.
Partly, yes. Based on ValueRay Analyses, Exchange Listed Funds Trust (NYSE ARCA:BCUS) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 43.62 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BCUS as of March 2025 is 26.54. This means that BCUS is currently overvalued and has a potential downside of -8.95%.
Exchange Listed Funds Trust has no consensus analysts rating.
According to ValueRays Forecast Model, BCUS Exchange Listed Funds Trust will be worth about 28.7 in March 2026. The stock is currently trading at 29.15. This means that the stock has a potential downside of -1.65%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 28.7 | -1.6% |